2-deoxyglucose (2-DG), a glycolysis inhibitor, has previously been shown to exhibit anti-inflammatory and anti-arthritic properties. However, the specific mechanisms of inflammatory modulation by 2-DG remain un
Jain VK, Kalia VK, Sharma R, Maharajan V, Menon M (1985) Effects of 2-deoxy-D-glucose on glycolysis, proliferation, kinetics and radiation response of human cancer cells. Int J Radiat Oncol Biol Phys 11:943–950Jain VK, Kalia VK, Sharma R, et al: Effects of 2-deoxy-D-glucose on ...
2-Deoxy-D-glucose (2-DG, with 97% purity) and HIF-1α inhibitor (YC-1, with 99.94% purity) were obtained from Selleck Chemicals LLC. Sigma-Aldrich LLC provided polyvinylidene fluoride membrane with a pore size of 0.45 μm. Cell culture and treatment Tubular epithelial cells are the core...
The tumor-bearing mice were intraperitoneally given 2-deoxy-d-glucose (2-DG), an inhibitor of hexokinase, at a dose of 1 g/kg body weight or DPBS (ctrl) every other day starting at second week after 4T1-tumor inoculation. Treatment of 2-DG for 1 week already significantly reduced ...
4I). By employing a glycolysis inhibitor, 2-deoxy-D-glucose (2-DG), to obstruct glucose availability, we observed a reduction in the expression of pro-inflammatory factors in macrophages(Fig. 4J). To further confirm our findings, we treated Irf7-knockdown macrophages with knockdown or ...
We used the glycolytic inhibitor 2-deoxy-D-glucose (2-DG) to block glucose supply and found that in macrophages with inhibited CXCR4 expression, the expression of IL-1β, IL-6, TNF-α, and iNOS decreased while arginase-1 increased (Fig. 3I). These results indicate that CXCR4 can alter...
Our findings indicated that combining PF with an inhibitor of its glycolytic adaptation (inhibiting AMPK) may be a viable strategy for treating gallbladder cancer. Methods Reagents and antibodies The following reagents were used in the study: Penfluridol (PF), 2-Deoxy-D-glucose (2-DG), A-...
The anti-tumour agent lonidamine is a potent inhibitor of the mitochondrial pyruvate carrier and plasma membrane monocarboxylate transporters. Biochem J. 2016;473(7):929–36. Article CAS Google Scholar A Phase I/II Trial of 2-Deoxyglucose (2DG) for the treatment of advanced cancer and ...
5E). Inhibiting glycolysis with 2-DG (a HK2 inhibitor) and C3K (a PKM2 inhibitor) effectively decreased CCL26 expression (Fig. 5F, S5A); however, the inhibition of glycolysis with PFK15 (a PFKL inhibitor) did not induce CCL26 downregulation (Figure S5B). Treatment with 2-DG (Fig. 5G...
(Supplementary Fig.11d). Seahorse analysis of extracellular acidification rate (ECAR) validated the activation of glycolysis in SAA-associated neutrophils (Supplementary Fig.11e). Moreover, despite SAA incubation, PD-L1 can be downregulated by glycolysis inhibitor 2-Deoxy-D-glucose (2DG) in ...